Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017; 377: 2240-2252.
Published: 25th January 2018
Authors: Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ et al.
The study included 692 patients with proximal DVT. The rate of subsequent post thrombotic syndrome between six and 24 months after treatment was 47 per cent after thrombolysis and 48 per cent after anticoagulation alone. Major bleeding was more common after thrombolysis: 1.7 versus 0.3 per cent, P=0.049.Pubmed Link
You may also be interested in
Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382: 1599-1607
Authors: Agnelli G, Becattini C, Meyer G, Munoz A, Huisman MV, Connors JM et al.
Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. N Engl J Med 2019; 380: 1305-1315.
Authors: Arabi YM, Al-Hameed F, Burns KEA, Mehta S, Alsolamy SJ, Alshahrani MS et al.
Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: Systematic review and meta-analysis of randomized clinical trials. Surgery 2018; 164: 1234-1240.
Authors: Rausa E, Kelly ME, Asti E, Aiolfi A, Bonitta G, Winter DC et al.
Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380: 720-728.
Authors: Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T et al.
Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380: 711-719.
Authors: Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A et al.
Thromboembolism incidence and prophylaxis use after gastrectomy among Korean patients with gastric adenocarcinoma. The PROTECTOR randomized clinical trial. JAMA Surg 2018; 153: 939-946.
Authors: Jung YJ, Seo HS, Park CH, Jeon HM, Kim J-I, Yim HW et al.
Venous thromboembolism incidence and prophylaxis use after gastrectomy among Korean patients with gastric adenocarcinoma. The PROTECTOR randomized clinical trial. JAMA Surg 2018; 153: 939-946.
Authors: Jung YJ, Seo HS, Park CY, Jeon HM, Kim J-I, Yim HW et al.
Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol 2018; 1: e25-e33.
Authors: Ten Cate-Hoek AJ, Amin EE, Bouman AC, Meijer K, Tick LW, Middeldorp S et al.
Randomized double-blinded study comparing medical treatment versus iliac vein stenting in chronic venous disease. J Vasc Surg Venous Lymphatic 2018; 6: 183-191.
Authors: Rossi FH, Kambara AM, Izukawa NM, Rodrugues TO, Rossi CB, Sousa AG et al.
Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615-624.
Authors: Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al.
Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376: 1211-1222.
Authors: Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Bayer-Westendorf J, Bounameaux H et al.
Timing of chemical thromboprophylaxis and deep vein thrombosis in major colorectal surgery: a randomized clinical trial. Ann Surg 2016; 264: 632-639.
Authors: Zaghiyan KN, Sax HC, Miraflor E, Crossman D, Wagner W, Mirocha J et al.